| Literature DB >> 17061154 |
Ismail Simsek1, Salih Pay, Ayhan Dinc, Hakan Erdem, Bulent Kurt.
Abstract
Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17061154 DOI: 10.1007/s10067-006-0454-4
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980